Effect of Astaxanthin Phytochemical, Vitamin D3, Omega-3 and Vitamin E supplement on severity of mild to moderate COVID-19 Symptoms

Assessing the effect of Astaxanthin Phytochemical, Vitamin D3, Omega-3 and Vitamin E ?upplement on the severity of COVID-19 Symptoms of Patients with mild to Moderate Severity- a randomized double blind controlled Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140804018677N9

Enrollment

Registered

2021-06-19

Start date

2021-05-28

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: 20 mg Astaxanthin, 200 mg omeg-3, 30 mg vitamin E, and 1000 IU vitamin D per cap for 7 days, BD. Intervention 2: Control group: placebo containing maltodextrine-for

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Positive test for COVID-19 according to WHO criteria and diagnosed with COVID-19 of mild to moderate severity Willingness to participate in the project age>18 years

Exclusion criteria

Exclusion criteria: Diagnosed with severe COVID-19 according to WHO criteria Pregnancy Using Omega-3 and/or vitamin E in 2 months before study initiation Vitamin D deficiency PN or EN need Need for ICU admission

Design outcomes

Primary

Measure	Time frame
Respiratory rate. Timepoint: baseline and at the end of the study. Method of measurement: pulsoximeter.;Pulse rate. Timepoint: baseline and at the end of the study. Method of measurement: Wrist radial atrial pulse.;Interlukin-6. Timepoint: baseline and at the end of the study. Method of measurement: ELISA.;Tumor necrotising factor alpha. Timepoint: baseline and at the end of the study. Method of measurement: ELISA.	—

Measure

Time frame

Respiratory rate. Timepoint: baseline and at the end of the study. Method of measurement: pulsoximeter.;Pulse rate. Timepoint: baseline and at the end of the study. Method of measurement: Wrist radial atrial pulse.;Interlukin-6. Timepoint: baseline and at the end of the study. Method of measurement: ELISA.;Tumor necrotising factor alpha. Timepoint: baseline and at the end of the study. Method of measurement: ELISA.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSoodeh Razeghi Jahromi

Shahid Beheshti University of Medical Sciences

soodehrazeghi@gmail.com+98 21 2235 7483

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026